US IPO Pipeline SEC S-1 Filings — April 27, 2026

27-04-2026

Cintas Corporation (CTAS) entered into a merger agreement on March 10, 2026, to acquire UniFirst Corporation (UNF) through a two-step merger process, with UniFirst shareholders receiving $155.00 in cash and 0.7720 shares of Cintas common stock per UniFirst share. Cintas expects to issue approximately 14,261,683 shares, resulting in UniFirst shareholders owning 3.4% of the combined company post-merger, while current Cintas shareholders retain 96.6%. The UniFirst board unanimously recommends approval, supported by a voting agreement from the Croatti family controlling approximately two-thirds of UniFirst's voting power; a special shareholder meeting is scheduled for [•], 2026.

• ·UniFirst common stock trades on NYSE under symbol 'UNF'; Cintas common stock trades on NASDAQ under 'CTAS'.
• ·UniFirst special meeting to be held virtually on [•], 2026, at 10:00 a.m. ET; record date [•], 2026.
• ·Merger requires two-thirds approval of combined voting power of UniFirst shares; no appraisal rights for shareholders.
• ·UniFirst will delist from NYSE and deregister under Exchange Act post-merger.

27-04-2026

Picard Medical, Inc. (PMI) filed an S-1 registration statement on April 27, 2026, in preparation for an initial public offering, including financial statements for the years ended December 31, 2025 and 2024, with revenue segments for Products and Rentals. The filing discloses risks related to customer, product, and geographic concentrations (primarily US, Europe, other foreign countries including RS and CA), ongoing convertible notes (2023, 2024, 2025), senior secured notes, warrants, a reverse stock split effective July 1-11, 2025, and equity incentive plans. No specific financial performance metrics such as revenue growth or declines are quantified in the provided excerpt, limiting period-over-period analysis.

• ·Reverse stock split occurred from July 1 to July 11, 2025.
• ·Company incorporated on April 8, 2021.
• ·Tuscon, AZ lease disclosed for facilities.
• ·Conversions of Series A1 Preferred Stock, convertible notes, and aggregated notes into common stock occurred in July-September 2025 ahead of IPO.
• ·Customer concentrations: Customer A, B, I for sales; A, B, F, H for receivables in 2025.

27-04-2026

Envirotech Vehicles, Inc. filed an S-1 registration statement on April 27, 2026, to register shares for resale by the Selling Securityholder under an Amended and Restated Standby Equity Purchase Agreement (A&R SEPA) with a $25 million commitment, from which the company raised approximately $3,100,000 in Q4 2025 and Q1 2026 by issuing 5,431,083 shares, leaving $13.5 million available until November 1, 2027. The company is pivoting strategy toward power-driven AI data infrastructure and U.S.-made heavy-lift drone systems (payload ~500 pounds) in development since 2025, while moderating expansion in its commercial EV segment due to reduced incentives, import tariffs exceeding 100% on Asian components, and cost pressures. Other segments include stable medical supplies via Maddox Industries and exploratory data center initiatives in regions like South Texas.

• ·A&R SEPA entered October 31, 2024, amending Original SEPA from September 23, 2024.
• ·Engaged drone manufacturer in February 2025 for U.S.-made heavy-lift drone with IP transfer.
• ·EV manufacturing via third-party OEMs in China and Malaysia, with U.S. final assembly.
• ·Proceeds from SEPA sales to first repay Debentures, then for working capital and general corporate purposes.

27-04-2026

MOBIX LABS, INC filed an S-1 registration statement on April 27, 2026, disclosing financial data for periods including Q4 FY2025 (2025-10-01 to 2025-12-31), FY2025 (2024-10-01 to 2025-09-30), and prior year comparisons, covering balance sheet items such as redeemable convertible preferred stock (including Series A), common stock classes A and B, PP&E (equipment, furniture, laboratory equipment, leasehold improvements), intangibles (developed technology rights, customer relationships, trade names), backlog, and related/unrelated party notes payable. The filing details product and service revenue breakdowns, convertible notes, warrants, and leases without specific monetary values in the provided tags. No period-over-period performance metrics or growth/decline percentages are numerically quantified in the excerpt.

• ·Incorporation or key event date: 2023-12-21 for MobixLabsInc (2023-12-01 to 2023-12-21)
• ·Leases include LowellMassachusettsLease and four properties as of 2025-09-30
• ·Notes payable include 7% promissory notes to related parties, convertible notes convertible to Common Class A, and notes to unrelated investors/officers/directors
• ·Intangible assets with amortization periods (min/max) for developed technology rights, customer relationships, trade names as of 2025-12-31 and 2025-09-30
• ·Backlog reported as of 2025-09-30 and 2024-09-30

27-04-2026

Veradermics, a late-stage biopharma company, filed an S-1 registration statement disclosing positive topline data from its Phase 2/3 trial (Study ‘302’) in 519 male patients with pattern hair loss (PHL), meeting all co-primary endpoints with statistically significant non-vellus TAHC increases of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs. 7.3 hairs/cm² for placebo at Month 6 (p<0.0001), and high PRO response rates of 79.3%-86.0% vs. 35.6% placebo. The company has fully enrolled two male registration-directed trials (Phase 2/3: 519 patients; Phase 3: 536 patients) and initiated a female Phase 2/3 trial targeting 552 patients, with male Phase 3 topline data expected in H2 2026. The U.S. PHL market is estimated at $9 billion annually, with VDPHL01 positioned as a potential first oral, non-hormonal FDA-approved therapy.

• ·VDPHL01 is an oral ER formulation of minoxidil at 8.5 mg QD or BID; Phase 1 showed nearly twice the plasma exposure over 12 hours vs. 2.5 mg IR minoxidil, sustained above hair growth threshold 2x longer, with peak below cardiac threshold and no SAEs.
• ·All trials assess two dose regimens over 52 weeks; co-primary endpoints: non-vellus hair count change per cm² and PRO hair coverage benefit at 24 weeks.
• ·Earliest patent expiry: 2043.
• ·Rapid onset observed as early as Month 2 with statistical separation from placebo on TAHC and IGA.
• ·Treatment generally well-tolerated with TEAE rates similar to placebo, lower discontinuation rates than placebo, no treatment-related SAEs or cardiac AESIs.

27-04-2026

Syntec Optics Holdings, Inc. filed an S-1 registration statement on April 27, 2026, likely in connection with an IPO. The company faced multiple Nasdaq delinquency notices for late filings of its 2024 10-K and 2025 Q1/Q2 10-Qs but regained compliance by filing them on October 6, 2025. As a controlled company with Al Kapoor holding 82.80% voting power, it plans to rely on exemptions from certain Nasdaq governance rules, while outstanding warrants (14.1M public and 6.9M private at $11.50/share) and potential resale of nearly 31M shares pose dilution and downward price pressure risks.

• ·Company received Nasdaq delinquency notices on March 21, 2025, May 28, 2025, and August 29, 2025, with compliance deadline of October 13, 2025.
• ·Three customers represent customer concentration risk in accounts receivable and sales revenue for 2024 and 2025.
• ·Intends to rely on controlled company exemption for majority independent board requirement under Nasdaq Rule 5605(b)(1).

27-04-2026

Berto Acquisition Corp. II, a blank-check SPAC, filed an S-1 registration statement on April 27, 2026, for an initial public offering of 25,000,000 units, each consisting of one ordinary share and one-third of a warrant. Post-offering, ordinary shares will total 31,250,000 and warrants 11,833,333, including 3,500,000 private placement warrants. Founder shares totaling 7,187,500 were issued in December 2025 for $25,000, representing 20% ownership, with warrants exercisable at $11.50 per share starting 30 days after the initial business combination.

• ·Separate trading of ordinary shares and warrants prohibited until Form 8-K filed with audited balance sheet post-IPO closing.
• ·Warrants expire 5 years after initial business combination or earlier upon redemption/liquidation.
• ·Public warrants redeemable for $0.01 each if ordinary share price ≥ $18.00 for 20/30 trading days.
• ·Private placement warrants exercisable on same terms as public warrants.
• ·Founder shares purchased at ~$0.003 per share; up to 937,500 forfeitable if no over-allotment.
• ·Registration statement to be filed within 20 business days post-business combination for warrant shares.